| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 09/23/2003 | US6624174 2-amino-nicotinamide derivatives and their use as VEGF-receptor tyrosine kinase inhibitors |
| 09/23/2003 | US6624164 1,3-dihydro-2H-indol-2-one derivatives, preparation method and pharmaceutical composition containing them |
| 09/23/2003 | US6623947 Nucleotide sequences coding pancreatic protein; for use in the treatment of diabetes and pancreatic defects |
| 09/23/2003 | US6623730 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 09/23/2003 | CA2147482C Process for manufacturing crystals of growth hormone and crystals thereby obtained |
| 09/23/2003 | CA2106371C Process for the preparation of ergoline derivatives |
| 09/23/2003 | CA2073760C Steroidal organic substance crystallization method and compounds thereby obtained |
| 09/18/2003 | WO2003076443A1 Spiro compounds with npy antagonistic activity |
| 09/18/2003 | WO2003076438A1 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| 09/18/2003 | WO2003076430A1 Amino-derivatives as novel inhibitors of histone deacetylase |
| 09/18/2003 | WO2003076421A1 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 09/18/2003 | WO2003076407A1 Novel chalcone derivatives and uses thereof |
| 09/18/2003 | WO2003076406A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies |
| 09/18/2003 | WO2003076401A1 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| 09/18/2003 | WO2003076400A1 New inhibitors of histone deacetylase |
| 09/18/2003 | WO2003076398A2 Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors |
| 09/18/2003 | WO2003076397A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists |
| 09/18/2003 | WO2003075958A1 Remedies for sex hormone-dependent disease |
| 09/18/2003 | WO2003075948A1 NOVEL FUNCTION OF Wnt AND APPLICATION THEREOF TO TREATMENT OF DISEASES |
| 09/18/2003 | WO2003075945A2 Cg8327, cg10823, cg18418, cg15862, cg3768, cg11447 and cg16750 homologous proteins involved in the regulation of energy homeostasis |
| 09/18/2003 | WO2003075931A1 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus |
| 09/18/2003 | WO2003075929A1 Inhibitors of histone deacetylase |
| 09/18/2003 | WO2003075915A1 5-}2-hydroxy-3-`1-(3-trifluoromethylphenyl)-cyclopropyl!-propionylamino}- phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy |
| 09/18/2003 | WO2003075893A1 Controlled release dosage forms |
| 09/18/2003 | WO2003075887A1 Sustained release drug formulations containing a carrier peptide |
| 09/18/2003 | WO2003075885A1 Composition having gelling properties for the prolonged delivery of bioactive substances |
| 09/18/2003 | WO2003059283A3 Compounds for blocking androgen receptors |
| 09/18/2003 | WO2003046135A3 Osteopontin-related compositions and methods |
| 09/18/2003 | WO2003012139A3 Methods for assessing the risk of obesity based on allelic variations in the 5'-flanking region of the insulin gene |
| 09/18/2003 | WO2002066646A3 Neurotransmission-associated proteins |
| 09/18/2003 | WO2002062391A3 Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea |
| 09/18/2003 | WO2002059308A3 Method of diagnosing and treating cartilage disorders |
| 09/18/2003 | US20030176666 Hypothalamus-specific polypeptides |
| 09/18/2003 | US20030176491 For therapy and prophylaxis of prostatitis or interstitial cystitis, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometrial cancer |
| 09/18/2003 | US20030176485 Calcium receptor active compounds |
| 09/18/2003 | US20030176481 Novel imidazole derivatives with anti-inflammatory activity |
| 09/18/2003 | US20030176478 For selectively modulating the activation, repression, agonism and antagonism effects of the glucocorticoid receptor in a patient; for therapy and prophylaxis of obesity, diabetes, depression, neurodegeneration or an inflammatory disease |
| 09/18/2003 | US20030176476 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/18/2003 | US20030176416 For therapy of disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors |
| 09/18/2003 | US20030176407 Carbonate and carbamate modified forms of glucocorticoids |
| 09/18/2003 | US20030176405 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 09/18/2003 | US20030176363 For therapy of T lymphocyte mediated inflammatory diseases in animals and man |
| 09/18/2003 | US20030176360 For use in drugs used for therapy of prostate cancer, benign prostatic hyperplasia, endometriosis, hysteromyoma, metrofibroma, precocious puberty, breast cancer, and the like |
| 09/18/2003 | US20030176331 Having therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins; for therapy of cancer |
| 09/18/2003 | US20030175963 Platform for the differentiation of cells |
| 09/18/2003 | US20030175934 Controlling cell differentiation, cell proliferation; anticancer agents |
| 09/18/2003 | US20030175920 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 09/18/2003 | US20030175817 Method of screening for antiandrogen agent |
| 09/18/2003 | US20030175373 Osteoporosis therapy; plant extract |
| 09/18/2003 | US20030175280 Antagonists to chaperonin 10 |
| 09/18/2003 | CA2482191A1 Spiro compounds with npy antagonistic activity |
| 09/18/2003 | CA2479065A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists |
| 09/18/2003 | CA2478948A1 5-}2-hydroxy-3-`1-(3-trifluoromethylphenyl)-cyclopropyl!-propionylamino}-phtalide and related compounds with progesterone receptor modulating a ctivity for use in fertility control and hormone replacement therapy |
| 09/18/2003 | CA2478931A1 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus |
| 09/18/2003 | CA2478921A1 Novel chalcone derivatives and uses thereof |
| 09/18/2003 | CA2478827A1 Remedies for sex hormone-dependent disease |
| 09/18/2003 | CA2478652A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies |
| 09/18/2003 | CA2477984A1 Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors |
| 09/18/2003 | CA2477701A1 Controlled release dosage forms |
| 09/18/2003 | CA2474613A1 Sustained release drug formulations containing a carrier peptide |
| 09/17/2003 | EP1344529A1 Therapeutic compositions for treating male pattern baldness |
| 09/17/2003 | EP1343806A1 Methylene steroids as novel androgens |
| 09/17/2003 | EP1343804A1 14(15)-unsaturated 15- and/or 16- substituted androgens with mixed androgen-progestational profile |
| 09/17/2003 | EP1343781A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 09/17/2003 | EP1343763A1 Pyrodone derivatives as ap2 inhibitors |
| 09/17/2003 | EP1343759A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 09/17/2003 | EP1343521A2 Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations |
| 09/17/2003 | EP1343509A2 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
| 09/17/2003 | EP1343508A1 Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis |
| 09/17/2003 | EP1343493A2 Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| 09/17/2003 | EP1343488A1 Treatment of statin side effects |
| 09/17/2003 | EP1343483A2 Transdermal system containing a novel high potency progestagen |
| 09/17/2003 | EP1282622B1 Crf receptor antagonists and methods relating thereto |
| 09/17/2003 | EP1150662B1 Laminates containing an active substance for transdermal systems |
| 09/17/2003 | EP1009755B1 Steroid sulfatase inhibitors and methods for making and using the same |
| 09/17/2003 | EP0571613B1 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| 09/17/2003 | CN1443241A Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, proteins encoded, and uses thereof |
| 09/17/2003 | CN1443198A Ghrelin拮抗剂 Ghrelin Antagonist |
| 09/17/2003 | CN1443195A LHRH-antagonists, production and use thereof as medicament |
| 09/17/2003 | CN1443187A Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 09/17/2003 | CN1443178A (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl] -4-morpholibenzamide |
| 09/17/2003 | CN1443078A Testosterone ester formulation for human use |
| 09/17/2003 | CN1443065A Pharmaceutical composition improved in peroral absorbability |
| 09/17/2003 | CN1121413C Polypeptide compounds containing D-2-alkyltryptophan capable of promoting the release of growth hormone |
| 09/17/2003 | CN1121385C Haphthyl compounds, intermediates, compositions and methods of use |
| 09/17/2003 | CN1121379C Synthesis and use of retinene derivative having negative hormone and/or antagonist activities |
| 09/17/2003 | CN1121226C Chinese medicine for preventing and treating iatrogenic hypercortisonism |
| 09/16/2003 | US6620963 TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY |
| 09/16/2003 | US6620802 Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist |
| 09/16/2003 | US6620801 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 09/16/2003 | US6620422 Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period |
| 09/16/2003 | CA2249009C Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
| 09/16/2003 | CA2182183C Treatment of ovarian estrogen dependent conditions |
| 09/12/2003 | WO2003074681A1 Recombinant spores |
| 09/12/2003 | WO2003074485A2 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors |
| 09/12/2003 | WO2003074058A1 Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery |
| 09/12/2003 | WO2003074008A2 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/12/2003 | WO2003073986A2 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/12/2003 | WO2003051333B1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents |
| 09/12/2003 | WO2003041757A3 Catheter injectable depot compositions and uses thereof |